0n 15 June 2022 the European High Performance Computing Joint Undertaking (EuroHPC JU) announced the selection of five new sites which will host the next generation of European supercomputers, including the first European exascale supercomputer, JUPITER. These new systems will power new applications in a wide range of areas, from designing medicines and new materials to fighting climate change.
The inauguration of these new sites is relevant for the in silico medicine community as it is a clear sign that the EU is willing not only to invest in this kind of system but also to highlight and promote the role of supercomputers in tackling societal challenges and promoting medical and biomolecular research.
The press release specifically highlights personalised medicine and the development of new drugs as key uses of the supercomputers, emphasizing the increasing recognition of the health potential of computer modelling and simulation through HPCs.
Key highlights
